期刊文献+

EPOCH方案治疗复发及耐药中高度恶性非霍奇金淋巴瘤20例 被引量:3

原文传递
导出
摘要 目的观察EPOCH方案治疗复发耐药的中高度恶性非霍奇金淋巴瘤(NHL)的疗效及患者不良反应。方法选择经病理检查确诊的复发及耐药的NHL患者20例,应用EPOCH方案化疗:依托泊苷(VP16)每天50mg/m^2、多柔比星(ADM)/吡柔比星(THP)每天10mg/m^2、长春新碱(VCR)每天0.4mg/m^2同时溶于生理盐水500ml中持续静脉滴注24h,第1天至第4天;环磷酰胺(CTX)750mg/m^2,静脉滴注,第5天;泼尼松每天60mg/m^2,口服,第1天至第5天;21d为1个疗程。结果20例患者总有效率60%,完全缓解(CR)率25%,部分缓解(PR)率35%,主要不良反应为骨髓抑制。结论EPOCH方案是复发耐药NHL的有效解救方案,持续静脉滴注可加强杀伤肿瘤细胞的作用,不良反应小,方便经济,值得推广。
作者 李岭
出处 《白血病.淋巴瘤》 CAS 2009年第3期173-174,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献4

  • 1Messori A, Trippoli S, Valani M, et al. Survival in patients with intermediate or high grade non-Hodgkin lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer, 2001, 84: 303-307.
  • 2Lai GM, Chen YN, Mickley LA, et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer, 1991, 49: 696-673.
  • 3Wilder DD, Ogden JL, Jain VK, et al. A muhicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non- Hodgkin's lymphoma. Clin Lymphoma, 2001, 1: 285-292.
  • 4彭玉龙,黄慧强,林旭滨,夏忠军,李宇红,王巍,何友兼,潘战和,姜文奇,管忠震.EPOCH方案治疗外周T细胞非霍奇金淋巴瘤的临床报告[J].癌症,2004,23(8):943-946. 被引量:11

二级参考文献12

  • 1Kim K,Kim WS,Jung CW,et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification [J]. Eur J Cancer,2002,38(1):75- 81.
  • 2Arrowsmith ER,Macon WR,Kinney MC,et al. Peripheral T-cell Lymphomas:clinical features and prognostic factors of 92 Cases defined by the Revised European American lymphoma classification [J]. Leuk Lymphoma,2003,44(2): 241- 249.
  • 3Gallamini A,Stelitano C,Calvi R,et al. Peripheral T-cell lymphoma unspecified(PTCL-U):a new prognostic model from a retrospective multicentric clinical study [J]. Blood,2004,103(7):2474- 2479.
  • 4Rudiger T,Weisenburger DD,Anderson JR,et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project [J]. Ann Oncol,2002,13(1):140- 149.
  • 5Gisselbrecht C,Gaulard P,Lepage E,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte(GELA) [J]. Blood,1998,92(1):76- 82.
  • 6Karakas T,Bergmann L,Stutte HJ,et al. Peripheral T-cell lymphomas respond well to vincristine,adriamycin,cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas [J]. Leuk Lymphoma,1996,24(1- 2):121- 129.
  • 7Liang R,Todd D,Chan TK,et al. Intensive chemotherapy for peripheral T-cell lymphomas [J]. Hematol Oncol,1992,10(3- 4):155- 161.
  • 8Melnyk A,Rodriguez A,Pugh WC,et al. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggresive non-Hodgkin's lymphoma [J].Blood,1997,89(12):4514- 4520.
  • 9Lai GM,Chen YN,Mickley LA,et al. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines [J]. Int J Cancer,1991,49(5):696- 703.
  • 10Gutierrez M,Chabner BA,Pearson D,et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas:an 8-year follow-up of study of EPOCH [J]. J Clin Oncol,2000,18(21):3633- 3642.

共引文献10

同被引文献15

  • 1王彦华,蔡华,翁香勤,孙婉玲,李大启.CHOP方案单用或联合美罗华治疗48例弥漫大B细胞淋巴瘤的随机对照临床研究[J].中国综合临床,2006,22(11):1030-1032. 被引量:17
  • 2Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med, 2002, 346: 235-242.
  • 3Lai GM, Chen YN, Mickley LA, et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer, 1991, 49: 696-703.
  • 4罗盛,沈志坚,钱红兰,俞康,胡旭东.EPOCH方案治疗复发或难治性侵袭性非霍奇金淋巴瘤的的近期疗效[J].浙江临床医学,2007,9(11):1527-1528. 被引量:2
  • 5Messod A, Trippoll S, Valani M, et al. Survival in patients withintermediate or high grade non-Hodgkin's lymphoma : meta-analysis ofrandomized studies comparing third generation regimens with CHOP[J]. BrJ Cancer, 2001,84(3 ): 303-307.
  • 6Lai GM,Chen YN,Mickley LA,et al. P-glycoprotein expression andsedule dependence of adriamycin cytotoxieity in human coloncarcinoma cell lines [ J ]. Int J Cancer, 1991,49 ( 5 ) : 696-673.
  • 7Wilder DD, Ogden JL, Jain VK, et al. A multicenter trial ofinfusional etoposide, doxorubicin, and vincristine withcyclophosphamide and prednisone ( EPOCH ) in patients withrelapsed non-Hodgkin's lymphoma [ J ]. Clin Lymphoma, 2001,1(4) : 285-292.
  • 8刘海宁,翟勇平,于亚平,等.EPOCH方案治疗初治侵袭性非霍奇金淋巴瘤的临床研究[J].中华血液学杂志,2012,33 (增刊):349-350.
  • 9Dunleavy K, Pittaluga S,Maeda LS, et al. Dose-adjusted EPOCH-Rituximab therapy in primary mediastinal B-cell lymphoma [ J ]. NEngl J Med, 2013, 368( 15): 1408-1416.
  • 10陈宁斌,吴晖,何鸿鸣,黄雪珍,杨瑜,陈道光,陈英,林剑扬,郑艳彬,邹思平.EPOCH方案治疗非霍奇金淋巴瘤临床研究[J].肿瘤基础与临床,2008,21(6):485-486. 被引量:2

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部